Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016', provides in depth analysis on Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) 
- The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Overview 7
Therapeutics Development 8
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Products under Development by Stage of Development 8
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Products under Development by Therapy Area 9
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Products under Development by Indication 10
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Products under Development by Companies 14
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Products under Development by Universities/Institutes 17
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development 25
Advenchen Laboratories LLC 25
Athenex Inc 26
Basilea Pharmaceutica Ltd 27
Pfizer Inc 28
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Drug Profiles 29
apatinib - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
bosutinib - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CCT-196969 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CCT-241161 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
eCF-506 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
KX-01 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
KX-02 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
PP-1 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecule to Inhibit c-Src Tyrosine Kinase for Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Inhibit Src Kinase for Oncology - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecules to Inhibit Src Tyrosine Kinase for Colon Cancer - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
UM-164 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Dormant Projects 49
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Discontinued Products 50
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Featured News & Press Releases 51
Oct 18, 2016: Athenex announces Xiangxue Pharmaceuticals, its KX-02 development partner in China, has achieved a regulatory milestone in that territory 51
Aug 24, 2016: NICE approves new cancer drug bosutinib for routine NHS use 51
Jul 26, 2016: LSK BioPharma Announces Successful Outcome from End-of-Phase 2 meeting with FDA 52
Jul 07, 2016: NICE approves first drug from old Cancer Drugs Fund 52
Jun 08, 2016: New compound shows potential for triple-negative breast cancer 53
May 23, 2016: Breast cancer drug discovery offers hope of new treatments 54
Sep 15, 2015: Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 55
Feb 18, 2015: Particle Sciences Manufactures Clinical Supplies for Kinex's Glioblastoma Therapeutic 55
Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 56
Dec 24, 2014: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 56
Dec 09, 2014: Pfizer Demonstrates New Data On BOSULIF at ASH 2014 57
Aug 11, 2014: Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 57
Jul 24, 2014: Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 58
Mar 30, 2014: Atlantic Research Group Client Kinex Pharmaceuticals Initiate Phase I Glioblastoma trial 59
Jan 09, 2014: Avillion Partners with Pfizer to Co-develop BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Assessment by Monotherapy/Combination Products, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Pipeline by Advenchen Laboratories LLC, H2 2016 25
Pipeline by Athenex Inc, H2 2016 26
Pipeline by Basilea Pharmaceutica Ltd, H2 2016 27
Pipeline by Pfizer Inc, H2 2016 28
Dormant Projects, H2 2016 49
Discontinued Products, H2 2016 50